Chemists Engineer Isoform-Selective HDAC4/HDAC7 Probes to Dissect Th17 Inflammation
- HDAC4 and HDAC7 are class IIa histone deacetylases with limited tissue expression, making them attractive, more selective epigenetic drug targets than broadly expressed HDAC family members.
- Both enzymes help drive the transcriptional program behind Th17 cell differentiation, a pathway linked to inflammatory bowel disease and other Th17-associated inflammatory conditions.
- Chemists reworked the metal-binding and hydrophobic contact regions of TMP269, a known class IIa scaffold, to build a new series of HDAC4/7-directed analogs.
- Reporter-gene, binding, and docking studies uncovered distinct structural features that separately steer potency toward HDAC4 versus HDAC7.
- The work delivered isoform-selective, potent compounds usable as chemical probes to separately study HDAC4 and HDAC7 function, and as starting points for Th17-targeted therapeutics.
Class IIa HDACs are the pseudo-catalytic oddballs of the family — barely any intrinsic deacetylase activity, so their biology runs largely through protein contacts rather than a clean catalytic pocket, which is why generic HDAC pharmacophores rarely discriminate them well. Building off TMP269 instead of starting de novo is the pragmatic call: it's a validated class IIa binder, so tuning the metal-binding warhead plus the adjacent hydrophobic contacts is a much more tractable SAR exercise than blind discovery. Pulling HDAC4 vs HDAC7 selectivity out of that is the real win — these two are highly homologous, and clean separation is notoriously hard. Most clinical HDAC drugs are pan- or Class I-selective, so isoform-pure IIa probes are genuinely useful tool compounds for picking apart Th17 biology, well before anyone's thinking about a lead.